

Finished Formulations Product List



***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patents related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

FORMULATIONS

OUR VISION
TO REACH 1.5 BILLION
PEOPLE ACROSS THE
GLOBE

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patents related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
A	ABIRATERONE ACETATE	Tablets	250 and 500 mg	Oncology	Filed
	ACALABRUTINIB	Tablets	100 mg	Oncology	Under Development
	APALUTAMIDE	Tablets	60 mg	Oncology	Filed
	APIXABAN	Tablets	2.5 and 5 mg	Cardiovascular	Filed
	APREMILAST	Tablets	10, 20 and 30 mg	Psoriasis	Filed
	ARFORMOTEROL	Inhalation Solution	15 mcg/2 ml	Respiratory	Under Registration
	ATOGEPA NT	Tablets	10, 30 and 60 mg	Migraine	Under Registration
	ATORVASTATIN	Tablets	10, 20, 40 and 80 mg	Cardiovascular	Filed
	AZACITIDINE	Injection	100 and 150 mg	Oncology	Filed
B	BARICITINIB	Tablets	1, 2 and 4 mg	Rheumatoid arthritis	Under Development
	BEMPEDOIC ACID	Tablets	180 mg	Cardiovascular	Filed
	BEMPEDOIC ACID+EZETIMIBE	Tablets	180 mg	Cardiovascular	Filed
	BENDAMUSTINE	RTD Injection	180 mg	Oncology	Filed
	BENDAMUSTINE	Injection	25, 100 mg/vial	Oncology	Filed
	BORTEZOMIB	Lyo Injection	3.5 mg	Oncology	Filed
	BRIMONIDINE	Ophthalmic Solution	0.03%	Ophthalmology	Filed
C	CABAZITAXEL	Injection	40 mg/ml (1.5 ml)	Oncology	Filed
	CABOZANTINIB	Tablets	20, 40 and 60 mg	Oncology	Under Development
	CALCITONIN	Liquid Injection	200 IU/ml	Paget's disease	Filed
	CAPECITABINE	Tablets	150 and 500 mg	Oncology	Filed
	CARBIDOPA + LEVODOPA	ER Capsules	36.3mg+145mg, 23.8mg+95mg, 48.8mg+195mg and 61.3mg+245mg	Central Nervous System	Filed
	CARBOPROST	PFS Injection	250 mcg/ml	Women’s health	Filed
	CARFILZOMIB	Injection	10, 30 and 60 mg	Oncology	Filed

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
	CARMUSTINE	Injection	100 mg	Oncology	Filed
	CELECOXIB	Oral Solution	25 mg/1 ml	Pain Management	Filed
	CINACALCET	Tablets	30, 60 and 90 mg	Endocrinology	Filed
	CIPROFLOXACIN + DEXAMETHASONE	Ear Drops	0.3% + 0.1% 7.5 ml	Otolaryngology (ENT)	Filed
	COLCHICINE	Tablets	0.6 mg	Central Nervous System	Filed
	CYCLOPHOSPHAMIDE	RTD Injection	0.5, 1 and 2 gm	Oncology	Filed
D	DABIGATRAN ETEXILATE	Capsules	75, 110 and 150 mg	Cardiovascular	Filed
	DAPAGLIFLOZIN	Tablets	5 and 10 mg	Anti-Diabetic	Filed
	DAPTOMYCIN	Injection	350 and 500 mg	Anti-Infective	Filed
	DASATINIB MONOHYDRATE	Tablets	20, 50, 70, 80, 100 and 140 mg	Oncology	Filed
	DECITABINE	Injection	50 mg/vial	Oncology	Filed
	DESMOPRESSIN	Injection	4 mcg/ml	Endocrinology/Urology	Filed
	DEXLANSOPRAZOLE	DR Capsules	30 and 60 mg	Gastroenterology	Under Development
	DIFLUPREDNATE	Eye Drops	0.05%	Ophthalmology	Filed
	DIMETHYL FUMARATE	Capsules	120 and 240 mg	Multiple sclerosis	Under Registration
	DOLUTEGRAVIR+LAMIVUDINE	Tablets	50 + 300 mg	HIV	Under Development
	DOLUTEGRAVIR+RILPIVIRINE	Tablets	50 + 25 mg	HIV	Under Development
E	EDARAVONE	Injection	60 mg/100 ml	Central Nervous System	Filed
	EDOABAN	Tablets	15, 30 and 60 mg	Cardiovascular	Filed
	ELIGLUSTAT	Capsules	84 mg	Type 1 Gaucher disease	Filed
	ELTROMBOPAG	Tablets	12.5, 25, 50 and 75 mg	Anemia	Filed
	EMPAGLIFLOZIN	Tablets	10 and 25 mg	Anti-Diabetic	Filed
	EMPAGLIFLOZIN + LINAGLIPTIN	Tablets	10 + 5 mg and 25 + 5 mg	Anti-Diabetic	Under Registration

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
E	ENZALUTAMIDE	Tablets	40 and 80 mg	Oncology	Filed
	ENZALUTAMIDE	Soft gel Capsules	40 mg	Oncology	Filed
	EPHEDRINE	Injection	50 mg/ml	Anti-Allergic	Filed
	EPINEPHRINE	Injection	10 mg/10 ml and 30 mg/30 ml	Anti-Allergic	Filed
	ESOMEPRAZOLE	DR Capsules	20 and 40 mg	Gastroenterology	Filed
	EVEROLIMUS	Tablets	2.5, 5, 7.5 and 10 mg	Oncology	Filed
F	FERRIC CARBOXY MALTOSE	Injection	50 mg/ml	Anemia	Filed
	FIDAXOMICIN	Tablets	200 mg	Anti-Infective	Under Development
	FINGOLIMOD	Capsules	0.5 mg	Multiple sclerosis	Filed
	FONDAPARINUX SODIUM	PFS Injection	"2.5 mg/0.5 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml and 10 mg/0.8 ml"	Cardiovascular	Filed
	FORMOTEROL FUMARATE	Inhalation Solution	20 mcg/2 ml	Respiratory	Filed
	FOSAPREPITANT	Injection	150 mg	Oncology (Supportive Care)	Filed
	FULVESTRANT RT	PFS Injection	250 mg/5 ml	Oncology	Filed
H	HYDROCORTISONE SODIUM SUCCINATE	Injection	100 mg	Anti-Inflammatory	Under Registration
I	IMATINIB	Capsules	100 and 400 mg	Oncology	Filed
	IMATINIB	Tablets	100 and 400 mg	Oncology	Filed
	ISOTRETINOIN	Capsules	10, 20, 30 and 40 mg	Acne	Filed
K	KETOROLAC	Injection	30 mg/ ml	Pain Management	Filed
	KETOROLAC	Tablets	10 mg	Pain Management	Filed
L	LACOSAMIDE	Injection	200 mg/20 ml	Central Nervous System	Filed
	LANSOPRAZOLE	OD Tablets	15 and 30 mg	Gastroenterology	Filed

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
	LATANOPROSTENE BUNOD	Ophthalmic Solution	0.024%	Ophthalmology	Filed
	LENALIDOMIDE	Capsules	2.5, 5, 10, 15, 20 and 25 mg	Oncology	Filed
	LENVATINIB	Capsules	4 and 10 mg	Oncology	Filed
	LETERMOVIR	Tablets	240 and 480 mg	Infectious Disease (CMV)	Under Development
	LINAGLIPTIN	Tablets	5 mg	Anti-Diabetic	Filed
	LINAGLIPTIN+METFORMIN	Tablets	2.5 mg/500 mg, 2.5 mg/ 850 mg and 2.5 mg/1 g	Anti-Diabetic	Filed
	LIRAGLUTIDE	Injection Pen	6 mg/ml (3 ml)	Obesity	Filed
	LIRAGLUTIDE	Injection Pen	6 mg/ml (3 ml)	Anti-Diabetic	Filed
	LOXOPROFEN	Powder for Oral Solution - Sachet	60 mg	Pain Management	Filed
	LOXOPROFEN	Tablets	60 mg	Pain Management	Filed
	LUMATEPERONE	Tablets	10.5, 21 and 42 mg	Central Nervous System	Filed
M	MIDOSTAURIN	Soft gel Capsules	25 mg	Oncology	Filed
N	NALOXONE	Injection	2 mg/2 ml	Central Nervous System	Filed
	NANO PACLITAXEL	Injection	100 mg	Oncology	Filed
	NAPROXEN	Tablets	275 and 550 mg	Pain Management	Filed
	NELARABINE	Injection	250 mg/50 ml	Oncology	Filed
	NEOSTIGMINE	Injection	0.5 mg/1 ml, 1 mg/ ml and 3 mg/3 ml	Myasthenia gravis	Filed
	NICOTINE	Mini Lozenges	2 and 4 mg	Smoking Cessation	Under Development
	NILOTINIB	Capsules	50, 150 and 200 mg	Oncology	Filed
	NINTEDANIB	Soft gel Capsules	100 and 150 mg	Oncology	Filed
O					
	OLAPARIB	Tablets	100 and 150 mg	Oncology	Under Development
P					
	PALBOCICLIB	Tablets	75, 100 and 125 mg	Oncology	Filed
	PALBOCICLIB	Capsules	75, 100 and 125 mg	Oncology	Filed

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
	PALONOSETRON	Injection	0.075 mg/5 ml and 0.25 mg/ 5 ml	Anti-Emetic	Filed
	PAZOPANIB	Tablets	200 and 400 mg	Oncology	Filed
	PEMETREXED	Injection	100 mg/vial, 500 mg/vial and 1 g/vial	Oncology	Filed
	PLERIXAFOR	Injection	24 mg/1.2 ml	Oncology (Supportive Care)	Filed
	POMALIDOMIDE	Capsules	1, 2, 3 and 4 mg	Oncology	Filed
	POSACONAZOLE	DR Tablets	100 mg	Anti-Infective	Filed
	PRALATREXATE	Injection	20 mg/ml and 40 mg/2 ml	Oncology	Filed
	PREDNISOLONE ACETATE	Ophthalmic Suspension	1%	Ophthalmology	Under Development
R	REGADENOSON	Injection	0.4 mg/5 ml	Cardiovascular	Filed
	REGORAFENIB	Tablets	40 mg	Oncology	Filed
	RELUGOLIX	Tablets	120 mg	Oncology	Filed
	RIFAXIMIN	Tablets	550 mg	Anti-Infective	Under Development
	RIVAROXABAN	Tablets	2.5, 10, 15 and 20 mg	Cardiovascular	Filed
S	SACUBITRIL+VALSARTAN	Tablets	24/26, 49/51 and 97/103 mg	Cardiovascular	Filed
	SAPROPTERIN	Powder for Oral Solution	100 mg	Phenylketonuria	Under Registration
	SAPROPTERIN	Tablets	100 mg	Phenylketonuria	Under Registration
	SELATOGREL	Injection	16 mg/0.5 ml	Cardiovascular	Early stage of Development
	SEMAGLUTIDE	Injection	2 mg/1.5 ml, 2 mg/3 ml, 4 mg/3 ml and 8 mg/3 ml	Anti-Diabetic	Filed
	SEMAGLUTIDE	Tablets	3, 7 and 14 mg	Anti-Diabetic	Filed
	SEMAGLUTIDE	Tablets	1.5, 4 and 9 mg	Anti-Diabetic Obesity	Under Development
	SEMAGLUTIDE	Injection Pen	1 mg/1.5 ml, 2 mg/1.5 ml, 4 mg/3 ml, 6.8 mg/3 ml and 9.6 mg/3 ml	Obesity	Under Development
	SEVELAMER	Powder for Oral Suspension	800 mg and 2.4 gm	Urology	Filed

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
	SEVELAMER	Tablets	800 mg	Urology	Filed
	SIPONIMOD	Tablets	0.25, 1 and 2 mg	Multiple sclerosis	Filed
	SIROLIMUS	Tablets	1, 2 mg	Immunosuppressant	Filed
	SITAGLIPTIN	Tablets	25, 50 and 100 mg	Anti-Diabetic	Filed
	SITAGLIPTIN +METFORMIN	Tablets	50 + 500 mg and 50 + 1000 mg	Anti-Diabetic	Filed
	SODIUM NITROPRUSSIDE	Injection	50 mg/2 ml	Cardiovascular	Filed
	SORAFENIB	Tablets	200 mg	Oncology	Filed
	SUGAMMADEX	Injection	100 mg/ml (2 ml and 5 ml)	Central Nervous System	Filed
	SUNITINIB	Capsules	12.5, 25, 37.5 and 50 mg	Oncology	Filed
T	TAFAMIDIS MEGLUMINE	Soft gel Capsules	21 mg	Cardiovascular	Under Registration
	TAPINAROF	Cream	1%	Plaque psoriasis	Under Development
	TELMISARTAN + AMLODIPINE	Tablets	40 + 5 mg, 40 + 10 mg, 80 + 5 mg and 80 + 10 mg	Cardiovascular	Filed
	TERIPARATIDE	Injection	0.25 mg/ml (2.4 ml)	Anti-Osteoporosis	Filed
	TICAGRELOR	Tablets	60 and 90 mg	Cardiovascular	Filed
	TIMOLOL MALEATE	Ophthalmic Gel forming Solution	0.25% and 0.50%	Ophthalmology	Filed
	TOPIRAMATE	XR Capsules	25, 50, 100 and 200 mg	Central Nervous System	Filed
	TREPROSTINIL	Injection	1 mg/ml, 2.5 mg/ml, 5 mg/ml and 10 mg/ml (20 ml)	Cardiovascular	Filed
	TRIAMCINOLONE ACETONIDE	Injection	50 mg/5 ml, 40 mg/1ml, 200 mg/5 ml and 400 mg/10 ml	Anti-Inflammatory	Filed
U	TRILACICLIB DIHYDROCHLORIDE	Injection	300 mg	Oncology	Filed
	UPADACITINIB	ER Tablets	15, 30 and 45 mg	Rheumatoid arthritis	Under Development
	UPADACITINIB	Oral Solution	1 mg/ml	Rheumatoid arthritis	Under Development

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets

PRODUCT NAME*		DOSAGE FORM	STRENGTH	INDICATION/ THERAPY /DISEASE AREA	LEAD “MARKET DOSSIER” STATUS#
V	VALGANCICLOVIR	Tablets	450 mg	Anti-Viral	Filed
	VARENICLINE	Tablets	0.5 and 1 mg	Smoking cessation	Filed
	VASOPRESSIN	Injection	20 IU/ml	Endocrinology	Filed
	VIGABATRIN	Powder for Oral Solution - Sachet	500 mg	Central Nervous System	Filed
	VIGABATRIN	Tablets	500 mg	Central Nervous System	Filed
	VITAMIN K1	Injection	10 mg/ml	Hematology	Filed
	VOCLOSPORIN	Soft Gel Capsules	7.9 mg	Nephrology	Under Registration
	VONOPRAZAN	Tablets	10 and 20 mg	Gastroenterology	Under Registration
	VORICONAZOLE	Tablets	50 and 200 mg	Anti-Infective	Filed
Z	ZAFIRLUKAST	Tablets	10 and 20 mg	Respiratory	Filed

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy’s sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patent related liabilities. Dr. Reddy’s disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Lead Market Dossier means Dossier submitted to SRA (Stringent Regulatory Authorities) markets



api.drreddys.com | api@drreddys.com

Published date: 2nd July, 2026

***Disclaimer:** No information in this catalogue, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patents Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including patents scenario in their respective markets and will be responsible for all patents related liabilities. Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.